Fluoropyrimidine resistance in colon cancer

Richard Gorlick, Debabrata Banerjee

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


A significant obstacle for the management of patients with colorectal cancer is intrinsic drug resistance or in patients that respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms. These include alterations in drug influx, drug efflux, intracellular metabolic activation, intracellular catabolism, through alterations in the drug's target or through numerous changes downstream of the target including alterations in genes involved in the regulation of the cell cycle, apoptosis or in DNA damage repair. In this article, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines are reviewed focusing on newer studies using tumor samples obtained from patients. Clinical trials that can potentially overcome the relevant mechanisms of resistance are described.

Original languageEnglish (US)
Pages (from-to)409-416
Number of pages8
JournalExpert Review of Anticancer Therapy
Issue number4
StatePublished - Aug 2002


  • 5-fluorouracil
  • Cell cycle
  • Dihydropyrimidine dehydrogenase
  • Drug resistance
  • Fluorodeoxyuridine
  • Methotrexate
  • Thymidine phosphorylase
  • Thymidylate synthase
  • Trinotecan
  • Uridine monophosphate kinase

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Fluoropyrimidine resistance in colon cancer'. Together they form a unique fingerprint.

Cite this